[go: up one dir, main page]

NO20031483L - Vaksine - Google Patents

Vaksine

Info

Publication number
NO20031483L
NO20031483L NO20031483A NO20031483A NO20031483L NO 20031483 L NO20031483 L NO 20031483L NO 20031483 A NO20031483 A NO 20031483A NO 20031483 A NO20031483 A NO 20031483A NO 20031483 L NO20031483 L NO 20031483L
Authority
NO
Norway
Prior art keywords
vaccine
Prior art date
Application number
NO20031483A
Other languages
English (en)
Norwegian (no)
Other versions
NO20031483D0 (no
Inventor
Brigitte Desiree Alberte Colau
Marguerite Deschamps
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of NO20031483D0 publication Critical patent/NO20031483D0/no
Publication of NO20031483L publication Critical patent/NO20031483L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20031483A 2000-10-02 2003-04-01 Vaksine NO20031483L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0024089.5A GB0024089D0 (en) 2000-10-02 2000-10-02 Novel compounds
PCT/EP2001/011326 WO2002028422A2 (fr) 2000-10-02 2001-10-01 Vaccin

Publications (2)

Publication Number Publication Date
NO20031483D0 NO20031483D0 (no) 2003-04-01
NO20031483L true NO20031483L (no) 2003-05-28

Family

ID=9900509

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031483A NO20031483L (no) 2000-10-02 2003-04-01 Vaksine

Country Status (16)

Country Link
US (1) US20040022808A1 (fr)
EP (1) EP1324769A2 (fr)
JP (1) JP2004510744A (fr)
KR (1) KR20030031200A (fr)
CN (1) CN1477971A (fr)
AU (1) AU2002213984A1 (fr)
BR (1) BR0114393A (fr)
CA (1) CA2427842A1 (fr)
CZ (1) CZ2003931A3 (fr)
GB (1) GB0024089D0 (fr)
HU (1) HUP0302643A2 (fr)
IL (1) IL155072A0 (fr)
NO (1) NO20031483L (fr)
PL (1) PL362705A1 (fr)
WO (1) WO2002028422A2 (fr)
ZA (1) ZA200302522B (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004028736D1 (de) 2003-06-20 2010-09-30 Microbix Biosystems Inc Verbesserungen bei der virusproduktion
MXPA06006947A (es) * 2003-12-17 2007-01-26 Wyeth Corp Metodos para producir virus de almacenamiento estable y composiciones inmunogenicas de estos.
CN1305526C (zh) * 2003-12-29 2007-03-21 薛平 乙型脑炎病毒裂解疫苗及其制备方法
US20080254065A1 (en) 2004-03-09 2008-10-16 Chiron Corporation Influenza Virus Vaccines
CN101365480B (zh) 2005-11-01 2014-11-05 诺华疫苗和诊断有限两合公司 经由β-丙内酯处理的残留细胞DNA水平降低的细胞衍生病毒疫苗
AU2006310163B2 (en) 2005-11-04 2011-09-15 Seqirus UK Limited Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
HUE051122T2 (hu) 2005-11-04 2021-03-01 Seqirus Uk Ltd Sejttenyészetben növesztett influenzavírusból elõállított nemvirion anti-géneket tartalmazó adjuvált vakcinák
NZ592713A (en) 2005-11-04 2012-12-21 Novartis Vaccines & Diagnostic Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9
WO2007052058A1 (fr) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Vaccins influenza comprenant des combinaisons d'adjuvants particulaires et d'immunopotentiateurs
EA014028B1 (ru) 2005-11-04 2010-08-30 Новартис Вэксинс Энд Диагностикс Срл Эмульсии, содержащие свободное поверхностно-активное вещество в водной фазе в качестве адъюванта сплит вакцин против гриппа
HUE049580T2 (hu) 2006-01-27 2020-09-28 Seqirus Uk Ltd Hemagglutinint és mátrixfehérjéket tartalmazó, influenza elleni oltóanyagok
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP4585610A3 (fr) 2006-09-11 2025-09-24 Seqirus UK Limited Fabrication de vaccins contre le virus de la grippe sans utiliser d'oeufs
US20110053248A1 (en) * 2006-10-23 2011-03-03 Medimmune, Llc Serum-Free Virus Propagation Platform For A Virus Vaccine Candidate
PL2121011T3 (pl) 2006-12-06 2014-10-31 Novartis Ag Szczepionki zawierające antygeny czterech szczepów wirusa grypy
CN101784283A (zh) 2007-06-27 2010-07-21 诺华有限公司 低添加流感疫苗
SI2192917T1 (sl) * 2007-08-28 2014-05-30 Baxter International Inc. Postopek za proizvodnjo virusnih cepiv
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
US8685654B2 (en) 2007-12-24 2014-04-01 Novartis Ag Assays for adsorbed influenza vaccines
EA201071086A1 (ru) 2008-03-18 2011-04-29 Новартис Аг Усовершенствованный способ получения вакцинных антигенов вируса гриппа
WO2010052214A2 (fr) 2008-11-05 2010-05-14 Glaxosmithkline Biologicals S.A. Nouveau procédé
WO2010079081A1 (fr) 2009-01-07 2010-07-15 Glaxosmithkline Biologicals S.A. Procédés de récupération d'un virus ou d'un antigène viral produit par culture cellulaire
CA2750055A1 (fr) 2009-02-06 2010-08-12 Glaxosmithkline Biologicals S.A. Procede de purification de virus au moyen d'un gradient de densite
EP3173097A3 (fr) 2009-02-10 2017-07-12 Seqirus UK Limited Vaccins contre la grippe dotés de quantités réduites de squalène
EP2396031A1 (fr) 2009-02-10 2011-12-21 Novartis AG Vaccins contre l'influenza possédant des quantités accrues d'antigène h3
US20120093859A1 (en) 2009-02-10 2012-04-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
CN102548577A (zh) 2009-04-27 2012-07-04 诺华有限公司 用于抵抗流感的佐剂疫苗
ES2394797T3 (es) 2009-05-21 2013-02-05 Novartis Ag Genética inversa usando promotores no endógenos de pol l
JP5716297B2 (ja) 2009-06-25 2015-05-13 Jnc株式会社 クロマトグラフィー用充填剤、その製造方法、およびそれを用いたウイルス用ワクチンの製造方法
AU2010277310B2 (en) 2009-07-31 2015-01-15 Seqirus UK Limited Reverse genetics systems
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
WO2011036220A1 (fr) 2009-09-25 2011-03-31 Glaxosmithkline Biologicals S.A. Test d'immunodiffusion pour virus de la grippe
JP5871806B2 (ja) 2009-10-20 2016-03-01 ノバルティス アーゲー ウイルスレスキューのための改善された逆遺伝学
ES2562818T3 (es) 2010-05-03 2016-03-08 Glaxosmithkline Biologicals S.A. Procedimiento de inactivación del virus de la gripe
EP2566323A2 (fr) 2010-05-06 2013-03-13 Novartis AG Composés peroxydes organiques destinés à l'inactivation de microorganismes
EP2571520B1 (fr) 2010-05-21 2018-04-04 Seqirus UK Limited Méthode destinée au réassortiment du virus influenza
AU2011262312B2 (en) 2010-06-01 2015-05-28 Novartis Ag Concentration and lyophilization of influenza vaccine antigens
AU2011262309B2 (en) 2010-06-01 2015-08-13 Seqirus UK Limited Concentration of influenza vaccine antigens without lyophilization
WO2011154976A2 (fr) 2010-06-08 2011-12-15 Panacea Biotec Limited Vaccin antigrippal amélioré
US9517205B2 (en) 2010-08-20 2016-12-13 Seqirus UK Limited Soluble needle arrays for delivery of influenza vaccines
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
WO2013057715A1 (fr) 2011-10-20 2013-04-25 Novartis Ag Vaccins avec adjuvant contre le virus grippal b pour primo-vaccination pédiatrique
ES2628301T3 (es) 2012-03-02 2017-08-02 Seqirus UK Limited Recombinación de virus de gripe
CA2866465A1 (fr) 2012-03-06 2013-09-12 Crucell Holland B.V. Vaccination amelioree contre la grippe
HK1208502A1 (en) 2012-06-04 2016-03-04 Novartis Ag Improved safety testing
WO2014019718A1 (fr) 2012-08-01 2014-02-06 Bavarian Nordic A/S Vaccin contre le virus respiratoire syncytial (vrs) à base de virus de la vaccine ankara modifié (mva) recombinant
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
EP2925356A2 (fr) 2012-12-03 2015-10-07 Novartis AG Réassortiment du virus de la grippe
AU2014204826A1 (en) 2013-01-10 2015-07-09 Seqirus UK Limited Influenza virus immunogenic compositions and uses thereof
US10232031B2 (en) 2013-03-13 2019-03-19 Seqirus UK Limited Influenza virus reassortment
WO2014180999A1 (fr) 2013-05-10 2014-11-13 Novartis Ag Évitement du risque de narcolepsie dans les vaccins contre la grippe
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
BR112015030582A2 (pt) 2013-06-06 2017-08-29 Novartis Ag Segmento de hemaglutinina da gripe quimérico e de neuraminidase quimérico, proteína de hemaglutinina quimérica, vírus da gripe rearranjado, métodos para preparação de um vírus da gripe rearranjado e para preparação de uma vacina e sistema de expressão
US10392603B2 (en) 2013-08-30 2019-08-27 The Chemo-Sero-Therapeutic Research Institute Method of viral purification
EP3068791B1 (fr) 2013-11-15 2020-07-29 Novartis AG Élimination des impuretés de culture cellulaire résiduelle
CN105250280B (zh) 2014-07-14 2020-03-10 诺维科国际控股股份有限公司 包含辛苯聚醇和喹诺里西啶生物碱化合物或其来源的杀微生物组合物
FR3025107B1 (fr) 2014-08-29 2018-10-05 Calixar Procede de preparation d'un antigene vaccinal, antigene vaccinal obtenu et utilisations
JP6719468B2 (ja) 2014-12-16 2020-07-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 大規模なウイルス精製方法
BR112017028011A2 (pt) 2015-06-26 2018-08-28 Seqirus Uk Ltd vacinas de gripe correspondentes antigenicamente
CN108027371B (zh) 2015-07-07 2020-08-18 思齐乐 流感效力试验
CN107085095A (zh) * 2017-03-02 2017-08-22 江苏华冠生物技术股份有限公司 用作酶联试剂盒包被抗原的麻疹病毒裂解液的制备方法
US20220168413A1 (en) 2019-02-25 2022-06-02 Seqirus UK Limited Adjuvanted multivalent influenza vaccines
EP3941928A1 (fr) 2019-03-19 2022-01-26 Amgen Inc. Détergents alternatifs pour inactivation virale
AU2020380604A1 (en) 2019-11-07 2022-06-09 Seqirus UK Limited Compositions and methods for producing a viral vaccine with reduced particle size
MX2022006005A (es) 2019-11-18 2022-10-27 Seqirus Pty Ltd Metodo para producir virus de la influenza reagrupados.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4005528C2 (de) * 1990-02-22 1998-01-15 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung für Medien
NZ517903A (en) * 1999-09-24 2003-10-31 Smithkline Beecham Biolog S One dose intranasal influenza virus vaccine with split influenza viral antigens

Also Published As

Publication number Publication date
AU2002213984A1 (en) 2002-04-15
NO20031483D0 (no) 2003-04-01
CN1477971A (zh) 2004-02-25
WO2002028422A3 (fr) 2002-08-29
WO2002028422A2 (fr) 2002-04-11
HUP0302643A2 (hu) 2003-11-28
US20040022808A1 (en) 2004-02-05
CA2427842A1 (fr) 2002-04-11
PL362705A1 (en) 2004-11-02
GB0024089D0 (en) 2000-11-15
JP2004510744A (ja) 2004-04-08
EP1324769A2 (fr) 2003-07-09
CZ2003931A3 (cs) 2003-10-15
IL155072A0 (en) 2003-10-31
BR0114393A (pt) 2003-08-26
ZA200302522B (en) 2004-06-30
KR20030031200A (ko) 2003-04-18

Similar Documents

Publication Publication Date Title
NO20031483L (no) Vaksine
NO20024172L (no) Vaksine
PL363005A1 (pl) Szczepionki
NO20026175L (no) Vaksinesammensetning
NO20031705D0 (no) Vaksiner
NO20014325D0 (no) Vaksine
ATE290000T1 (de) Muscarinagonisten
ATE252099T1 (de) Biarylcarboxamide
ATE312098T1 (de) Thiazinoxazolidinon
NO20030447D0 (no) Brönnkontroll
ATA2932001A (de) Schneefräse
DK1427444T3 (da) West-nil-vaccine
DE60002650D1 (de) Öladjuvierter Impfstoff
NO20020763D0 (no) Vaksine
NO20033882D0 (no) Vaksine
ATE262530T1 (de) Indolochinazolinone
ATE298751T1 (de) 7-oxopyridoryrimidine
AR028336A1 (es) 4-hidroxi-tetrahidropiridonas fenilsubstituidas
ATE509008T1 (de) Sulfonylguanidine
NO20024322L (no) Sekvens
AR028061A1 (es) 2-enamino-cetonitrilos fenil-substituidos
AR027931A1 (es) Antitranspirantes
ATE476423T1 (de) Benzoylpyridazine
AR027982A1 (es) Aril- y heteroarilsulfonatos
ATE284887T1 (de) Thienopyrrolidinone

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application